Meanwhile, besides independent suppression of MAPK pathway, MEK blockers have also been combined with mTOR1/2, AKT, or CDK4/6 inhibitors in preclinical models or in clinical trials of MM (142–144). This evidence concerns the gene CDK4 and Miyoshi myopathy.